Deal Watch: GSK Makes $85m Wager On Surface’s Preclinical NK Cell Therapy
Although SRF813 isn’t likely to reach the clinic until 2021, GSK likes cell therapy’s monotherapy and combination potential. Lilly bids $880m to acquire neurodegenerative cell therapy firm Prevail.
You may also be interested in...
Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m.
GSK will pay iTeos $625m up front to codevelop and cocommercialize EOS-448, now in Phase I development for advanced solid tumors.
While the data are early, they have also generated positive views toward the company’s pipeline ahead of an anticipated CAR-NK data announcement at its investor meeting.